The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

A multicenter randomized, open-label, proof-of-concept, phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer.

Angus George  Dalgleish

Stock and Other Ownership Interests  - Celgene

Honoraria - Bristol-Myers Squibb; Celgene; TNI BioTech

Consulting or Advisory Role - Bionor Pharma; Celgene; CureVac; Immodulon Therapeutics; Ipsen; Novartis; PRMA Consulting; Roche; TNI BioTech

Speakers' Bureau - Bristol-Myers Squibb

Research Funding - Celgene; GW Pharmaceuticals; Immodulon Therapeutics

Patents, Royalties, Other Intellectual Property - Bionor Pharma; Celgene; GW Pharmaceuticals; TNI Bio Tech; Vulsana

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck